Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs

Bruce R. Schackman, Sarah Gutkind, Jake R. Morgan, Jared A. Leff, Czarina N. Behrends, Kevin L. Delucchi, Courtney Mcknight, David C. Perlman, Carmen L. Masson, Benjamin P. Linas

Research output: Contribution to journalArticle

Abstract

Background: We evaluated the cost-effectiveness of a hepatitis C (HCV) screening and active linkage to care intervention in US methadone maintenance treatment (MMT) patients using data from a randomized trial conducted in New York City and San Francisco. Methods: We used a decision analytic model to compare 1) no intervention; 2) HCV screening and education (control); and 3) HCV screening, education, and care coordination (active linkage intervention). We also explored an alternative strategy wherein HCV/HIV co-infected participants linked elsewhere. Trial data include population characteristics (67% male, mean age 48, 58% HCV infected) and linkage rates. Data from published sources include treatment efficacy and HCV re-infection risk. We projected quality-adjusted life years (QALYs) and lifetime medical costs using an established model of HCV (HEP-CE). Incremental cost-effectiveness ratios (ICERs) are in 2015 US$/QALY discounted 3% annually. Results: The control strategy resulted in a projected 35% linking to care within 6 months and 31% achieving sustained virologic response (SVR). The intervention resulted in 60% linking and 54% achieving SVR with an ICER of $24,600/QALY compared to no intervention from the healthcare sector perspective and was a more efficient use of resources than the control strategy. The intervention had an ICER of $76,500/QALY compared to the alternative strategy. From a societal perspective, the intervention had a net monetary benefit of $511,000–$975,600. Conclusions: HCV care coordination interventions that include screening, education and active linkage to care in MMT settings are likely cost-effective at a conventional $100,000/QALY threshold for both HCV mono-infected and HIV co-infected patients.

Original languageEnglish (US)
Pages (from-to)411-420
Number of pages10
JournalDrug and Alcohol Dependence
Volume185
DOIs
StatePublished - Apr 1 2018

Fingerprint

Quality-Adjusted Life Years
Methadone
Hepatitis C
Cost effectiveness
Cost-Benefit Analysis
Screening
Education
Patient treatment
HIV
Therapeutics
Costs and Cost Analysis
Health Care Sector
San Francisco
Information Storage and Retrieval
Costs
Population Characteristics
Infection

Keywords

  • Cost-effectiveness
  • Hepatitis C
  • Methadone maintenance therapy

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Schackman, B. R., Gutkind, S., Morgan, J. R., Leff, J. A., Behrends, C. N., Delucchi, K. L., ... Linas, B. P. (2018). Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug and Alcohol Dependence, 185, 411-420. https://doi.org/10.1016/j.drugalcdep.2017.11.031

Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. / Schackman, Bruce R.; Gutkind, Sarah; Morgan, Jake R.; Leff, Jared A.; Behrends, Czarina N.; Delucchi, Kevin L.; Mcknight, Courtney; Perlman, David C.; Masson, Carmen L.; Linas, Benjamin P.

In: Drug and Alcohol Dependence, Vol. 185, 01.04.2018, p. 411-420.

Research output: Contribution to journalArticle

Schackman, BR, Gutkind, S, Morgan, JR, Leff, JA, Behrends, CN, Delucchi, KL, Mcknight, C, Perlman, DC, Masson, CL & Linas, BP 2018, 'Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs', Drug and Alcohol Dependence, vol. 185, pp. 411-420. https://doi.org/10.1016/j.drugalcdep.2017.11.031
Schackman, Bruce R. ; Gutkind, Sarah ; Morgan, Jake R. ; Leff, Jared A. ; Behrends, Czarina N. ; Delucchi, Kevin L. ; Mcknight, Courtney ; Perlman, David C. ; Masson, Carmen L. ; Linas, Benjamin P. / Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. In: Drug and Alcohol Dependence. 2018 ; Vol. 185. pp. 411-420.
@article{793e688fe83b4b989e95d99625dd21a7,
title = "Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs",
abstract = "Background: We evaluated the cost-effectiveness of a hepatitis C (HCV) screening and active linkage to care intervention in US methadone maintenance treatment (MMT) patients using data from a randomized trial conducted in New York City and San Francisco. Methods: We used a decision analytic model to compare 1) no intervention; 2) HCV screening and education (control); and 3) HCV screening, education, and care coordination (active linkage intervention). We also explored an alternative strategy wherein HCV/HIV co-infected participants linked elsewhere. Trial data include population characteristics (67{\%} male, mean age 48, 58{\%} HCV infected) and linkage rates. Data from published sources include treatment efficacy and HCV re-infection risk. We projected quality-adjusted life years (QALYs) and lifetime medical costs using an established model of HCV (HEP-CE). Incremental cost-effectiveness ratios (ICERs) are in 2015 US$/QALY discounted 3{\%} annually. Results: The control strategy resulted in a projected 35{\%} linking to care within 6 months and 31{\%} achieving sustained virologic response (SVR). The intervention resulted in 60{\%} linking and 54{\%} achieving SVR with an ICER of $24,600/QALY compared to no intervention from the healthcare sector perspective and was a more efficient use of resources than the control strategy. The intervention had an ICER of $76,500/QALY compared to the alternative strategy. From a societal perspective, the intervention had a net monetary benefit of $511,000–$975,600. Conclusions: HCV care coordination interventions that include screening, education and active linkage to care in MMT settings are likely cost-effective at a conventional $100,000/QALY threshold for both HCV mono-infected and HIV co-infected patients.",
keywords = "Cost-effectiveness, Hepatitis C, Methadone maintenance therapy",
author = "Schackman, {Bruce R.} and Sarah Gutkind and Morgan, {Jake R.} and Leff, {Jared A.} and Behrends, {Czarina N.} and Delucchi, {Kevin L.} and Courtney Mcknight and Perlman, {David C.} and Masson, {Carmen L.} and Linas, {Benjamin P.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.drugalcdep.2017.11.031",
language = "English (US)",
volume = "185",
pages = "411--420",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs

AU - Schackman, Bruce R.

AU - Gutkind, Sarah

AU - Morgan, Jake R.

AU - Leff, Jared A.

AU - Behrends, Czarina N.

AU - Delucchi, Kevin L.

AU - Mcknight, Courtney

AU - Perlman, David C.

AU - Masson, Carmen L.

AU - Linas, Benjamin P.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: We evaluated the cost-effectiveness of a hepatitis C (HCV) screening and active linkage to care intervention in US methadone maintenance treatment (MMT) patients using data from a randomized trial conducted in New York City and San Francisco. Methods: We used a decision analytic model to compare 1) no intervention; 2) HCV screening and education (control); and 3) HCV screening, education, and care coordination (active linkage intervention). We also explored an alternative strategy wherein HCV/HIV co-infected participants linked elsewhere. Trial data include population characteristics (67% male, mean age 48, 58% HCV infected) and linkage rates. Data from published sources include treatment efficacy and HCV re-infection risk. We projected quality-adjusted life years (QALYs) and lifetime medical costs using an established model of HCV (HEP-CE). Incremental cost-effectiveness ratios (ICERs) are in 2015 US$/QALY discounted 3% annually. Results: The control strategy resulted in a projected 35% linking to care within 6 months and 31% achieving sustained virologic response (SVR). The intervention resulted in 60% linking and 54% achieving SVR with an ICER of $24,600/QALY compared to no intervention from the healthcare sector perspective and was a more efficient use of resources than the control strategy. The intervention had an ICER of $76,500/QALY compared to the alternative strategy. From a societal perspective, the intervention had a net monetary benefit of $511,000–$975,600. Conclusions: HCV care coordination interventions that include screening, education and active linkage to care in MMT settings are likely cost-effective at a conventional $100,000/QALY threshold for both HCV mono-infected and HIV co-infected patients.

AB - Background: We evaluated the cost-effectiveness of a hepatitis C (HCV) screening and active linkage to care intervention in US methadone maintenance treatment (MMT) patients using data from a randomized trial conducted in New York City and San Francisco. Methods: We used a decision analytic model to compare 1) no intervention; 2) HCV screening and education (control); and 3) HCV screening, education, and care coordination (active linkage intervention). We also explored an alternative strategy wherein HCV/HIV co-infected participants linked elsewhere. Trial data include population characteristics (67% male, mean age 48, 58% HCV infected) and linkage rates. Data from published sources include treatment efficacy and HCV re-infection risk. We projected quality-adjusted life years (QALYs) and lifetime medical costs using an established model of HCV (HEP-CE). Incremental cost-effectiveness ratios (ICERs) are in 2015 US$/QALY discounted 3% annually. Results: The control strategy resulted in a projected 35% linking to care within 6 months and 31% achieving sustained virologic response (SVR). The intervention resulted in 60% linking and 54% achieving SVR with an ICER of $24,600/QALY compared to no intervention from the healthcare sector perspective and was a more efficient use of resources than the control strategy. The intervention had an ICER of $76,500/QALY compared to the alternative strategy. From a societal perspective, the intervention had a net monetary benefit of $511,000–$975,600. Conclusions: HCV care coordination interventions that include screening, education and active linkage to care in MMT settings are likely cost-effective at a conventional $100,000/QALY threshold for both HCV mono-infected and HIV co-infected patients.

KW - Cost-effectiveness

KW - Hepatitis C

KW - Methadone maintenance therapy

UR - http://www.scopus.com/inward/record.url?scp=85044965353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044965353&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2017.11.031

DO - 10.1016/j.drugalcdep.2017.11.031

M3 - Article

C2 - 29477574

AN - SCOPUS:85044965353

VL - 185

SP - 411

EP - 420

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

ER -